Early Access — free while we kick the tires
EdgarHawk

Dandekar Atul

CSBO

Officer
1 filing analyzed · 1 company · Latest 2025-12-31

Companies

Company Buys Sells Direction
Maze Therapeutics, Inc. MAZE 0 5 Net selling

Activity

December 2025
high
Sell
72,500 shares
$2,940,799
Significance 7/10

MAZE Chief Scientific Officer Dandekar sells 72,500 shares (87.3% of holdings) for $2.9M at $40.56 avg

Dandekar, Chief Scientific Officer, executed 3 separate sales totaling 72,500 shares on 2025-12-29 and 2025-12-30 for $2,940,799.43, reducing his holdings from 83,003 to 10,503 shares. This represents a -87.3% reduction in position size at an average price of $40.56, near the current trading price of $41.43 and within 2.8% of the 52-week high of $42.60. The transaction occurs in the context of a company with zero revenue in the latest quarter and a -$30,087,000.00 net loss, while the stock has surged 56.3% over 90 days. The combination of a near-maximum liquidation by the chief scientific officer at peak valuation levels against an unprofitable, pre-revenue backdrop warrants investor attention to the company's path forward.

Related insiders

Create a free account

Build watchlists, get email alerts on the tickers you follow, and read the full AI analysis on every insider filing.

Sign up — free during early access